INDV.US Indivior PLC Ordinary Shares

Healthcare Biotechnology USA Stocks
36.28 USD
Close of Nov 15, 2026
21.48 37.01
Market cap
USD 4.28B
P/E
10.2x
P/B
145.25x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is INDV.US undervalued?

Graham number

The Graham number of Indivior PLC Ordinary Shares cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Indivior PLC Ordinary Shares fundamental analysis

No fundamental analysis for Indivior PLC Ordinary Shares yet.

Indivior PLC Ordinary Shares stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Indivior PLC Ordinary Shares

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorp…

Full company profile